Temozolomide Not Effective for Brain Metastases from Breast Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, whole-brain radiotherapy plus temozolomide does not improve local control, progression-free survival, or overall survival in patients with brain metastases from breast cancer.
For the multicenter, prospective, phase 2 study, researchers sought to investigate the safety and efficacy of whole-brain radiation therapy plus temozolomide for the treatment of patients with brain metastases from breast cancer.
They enrolled 100 patients with newly diagnosed intraparenchymal brain metastases from breast cancer who were not candidates for surgery or radiosurgery. Participants were randomly assigned to receive whole-brain radiation therapy with or without temozolomide. Patients were followed for a median of 9.4 months.
At 6 weeks, patients in combination arm achieved an objective response rate of 30% compared with 36% in the whole-brain radiation therapy alone group. Median progression-free survival for the combination group and radiation alone group were 6.9 months and 7.4 months, respectively. Median overall survival for those receiving radiation therapy plus temozolomide was 9.4 months versus 11.1 months among those receiving radiation alone.
Both treatments were well tolerated. The findings suggest that the addition of temozolomide to whole-brain radiation therapy for the treatment of brain metastases from breast cancer is not more effective that whole-brain radiation therapy alone.
Radiotherapy + temozolomide does not improve survival in patients with brain metastases from breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer